Recent studies suggest that KEAP1/NRF2 alterations in NSCLC serve as biomarkers of poor prognosis and contribute to resistance to various cancer treatments, such as chemotherapy, radiotherapy, immunotherapy, and TKI therapy (29). Here, NFE2L2 is linked to non-small cell lung carcinoma.